Vaccinex, Inc. Files 8-K Report
Ticker: VCNX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
VACCINEX FILES 8-K: Expect financial updates soon.
AI Summary
On June 6, 2024, Vaccinex, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing by Vaccinex, Inc. signals that the company is providing updated information to the SEC, which could include financial statements or exhibits relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38624 (filing_id) — Commission File Number
- 16-1603202 (tax_id) — IRS Employer Identification No.
- 1895 Mount Hope Avenue, Rochester, New York 14620 (address) — Principal executive offices
- (585) 271-2700 (phone_number) — Registrant's telephone number
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not specify which ones.
What is the primary purpose of this 8-K filing for Vaccinex, Inc. on June 6, 2024?
The primary purpose is to report current information under Regulation FD and to file financial statements and exhibits.
When was Vaccinex, Inc. incorporated, and in which jurisdiction?
Vaccinex, Inc. was incorporated in Delaware.
What is Vaccinex, Inc.'s principal executive office address and contact number?
The principal executive offices are located at 1895 Mount Hope Avenue, Rochester, New York 14620, and the telephone number is (585) 271-2700.
Does this filing indicate any new material events or changes in Vaccinex, Inc.'s business operations?
The excerpt indicates the filing is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', but does not detail any specific new material events.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-06 08:36:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
Filing Documents
- d756458d8k.htm (8-K) — 25KB
- d756458dex991.htm (EX-99.1) — 17KB
- g756458img01.jpg (GRAPHIC) — 6KB
- 0001193125-24-155612.txt ( ) — 172KB
- vcnx-20240606.xsd (EX-101.SCH) — 3KB
- vcnx-20240606_lab.xml (EX-101.LAB) — 17KB
- vcnx-20240606_pre.xml (EX-101.PRE) — 11KB
- d756458d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated June 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VACCINEX, INC. Date: June 6, 2024 By: /s/ Jill Sanchez Jill Sanchez Chief Financial Officer